ECTRIMS 2023 | Optimal DMT after natalizumab discontinuation

Maya Zeineddine, PharmD, Harley Street Medical Center, Abu Dhabi, United Arab Emirates, elucidates the significance of a study aimed at aiding clinicians when contemplating the discontinuation of natalizumab, especially in patients apprehensive of developing progressive multifocal leukoencephalopathy due to a positive JC virus test. The study’s primary goal was to determine the most effective drug to transition to after ceasing natalizumab, ensuring minimized risk of rebound activity. The results will provide evidence-based data, offering neurologists a concrete foundation when recommending an optimal successor therapy post-natalizumab. This robust, evidence-backed guidance will be invaluable in assuaging patient concerns and ensuring a seamless transition to safer yet effective disease-modifying therapies. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.